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Introduction 
Infection is a serious problem in several areas of 
medicine and appropriate antibiotic therapy is very 
crucial. Because of broad spectrum activity and 
low toxicity of β-lactam antibiotics, they are the 
most commonly used drugs against infections.1 
But over the past decade, bacterial resistance to 
antibiotics, especially β-lactam type, has been 
considered as the global healthcare concern. β-
lactam resistance occurs by the mobilization of 
genes that encode efficient drug modifying 
enzymes such as β-lactamase.2-5 
Extended-spectrum β-lactamases (ESBLs) are 
considered as one of the most prevalent 
mechanisms of resistance to β-lactam agents 
especially in enteric gram-negative bacilli.6,7 The 
enzymes, which are usually plasmid-encoded, have 
the ability to hydrolyze numerous β-lactam agents 
including penicillins, third-generation 
cephalosporins and aztreonam. They are inhibited 
by β-lactamase inhibitor including tazobactam and 
clavulanic acid.8,9 
These phenotypic features can assist to detection of 
ESBL-producing bacteria by routine laboratory 
methods such as double disk diffusion test.10 In 
addition, detection of specific genes is generally 
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applied for final verification. According to the 
literature, ESBLs production is related to presence 
of blaTEM, blaSHV, blaPER-1, blaGES and blaCTX 
genes.11,12 Some researchers reported that most 
ESBLs are originated from blaTEM and blaSHV 
genes.13 
ESBLs are frequently produced by Escherichia coli 
and Klebsiella pneumoniae isolates which are 
responsible for nosocomial and community-
acquired infections.14 E. coli is the most common 
causative microorganism of gastroenteritis, urinary 
tract infections and other hospital-acquired 
infections. Increasing the multidrug resistance 
strains is due to the widespread prescription of 
antibiotics against bacterial isolates.15,16 
Therefore, determination of antimicrobial 
susceptibility and ESBL production patterns are 
essential for treatment of related infections. 
Additionally, identification of the genetic 
relatedness among isolates can be helpful for 
infection source control and making preventive 
procedures. The aim of study was to determine the 
frequency of ESBL-producing E. coli and their 
genetic diversity, isolated from gastroenteritis 
patients admitted to clinical laboratory of Imam 
Khomeini Hospitals in Ilam, west of Iran. 
 
Materials and Methods 
Bacterial strains 
In this cross sectional study, 50 isolates of E. coli 
were collected from patients with diarrhea admitted 
to clinical laboratory of Imam Khomeini hospital in 
Ilam during July 2014 to January 2015. In order to 
genus confirmation, biochemical tests (oxidase, 
citrate, fermentation of glucose, lactose, motility, 
gas production, and SH2 production) were 
performed. 17 
Antimicrobial susceptibility 
Antibiotic sensitivity tests were done by disc 
diffusion method on Mueller Hinton agar (Merck 
Co, Germany) according to the Clinical Laboratory 
Standards Institute (CLSI) guideline 2015.18 The 
tested antibiotics (Mast Co., UK) were: imipenem 
(10 μg), gentamicin (10 μg), levofloxacin (5 μg), 
amikacin (30 μg), ciprofloxacin (5 μg) and 
trimethoprim/ sulfamethoxazole (1.25/23.75 μg). 
Phenotypic confirmatory test for determination of 
ESBL production 
Combined disc method was utilize for 
identification of ESBL-producing organisms 
according to CLSI guidelines.18 Briefly, sensitivity 
tests to cefotaxime (30 μg), cefotaxime/clavulanate 
(10 μg), ceftazidime (30 μg) and 
ceftazidime/clavulanate (10 μg) disks (Mast Co., 
UK) were determined on Muller-Hinton agar 
(Merck Co, Germany). The plates were incubated 
for 18-24 h at 37 °C. ESBL-producing strains were 
recognized by at least 5 mm increase in zone 
diameter around cefotaxim/clavulanate and 
ceftazidime/clavulanate disks compared to disks 
without clavulanic acid.19 Escherichia coli ATCC 
25922 was used as control strain. 
Molecular detection of ESBLs related genes 
DNA of the ESBL-producing isolates was 
extracted by boiling method. The PCR method for 
detection of blaSHV and blaTEM genes was carried 
out as described previously.20 Briefly, the PCR 
protocol was 30 cycles of 60 s at 95 °C, 45 s at 48 
°C (for blaSHV) and 50 °C (for blaTEM), and 45 s at 
72 °C. A final extension step was done at 72 °C for 
5 min. PCR products were separated by 
electrophoresis in 1% agarose gels. 
Oligonucleotide primers were mentioned in Table 
1. 
 
Molecular genotyping 
Randomly Amplified Polymorphic DNA (RAPD) 
analysis was also performed to identify genetic 
relatedness among isolates as described previously 
with a little modification. RAPD-PCR 
oligonucleotide primer was 5'-AAGAGCCCG-3'.21 
Briefly, the PCR protocol was a predenaturation 
step at 95 °C for 5 min, followed by 35 cycles of 60 
s at 95 °C, 45 s at 42 °C, and 50 s at 72 °C. A final 
extension step was performed at 72 °C for 5 min. 
PCR products were separated by electrophoresis in 
1.5% agarose gels. After agarose gel 
electrophoresis, banding patterns were analyzed by 
visual examination. Classification as a distinct 
RAPD type was based on difference between two 
or more band of each banding pattern. In other 
words, isolates were classified as identical RAPD 
types when their banding patterns were similar or 
different in one band only.22 
 
Statistical analysis 
Resistance to antimicrobial agents between ESBL-
producing and non ESBL-producing isolates was 
investigated by Chi-square test. A p-value of <0.05 
was considered as statistically significant.  
 
Table 1. Oligonucleotide primers used for ESBL detection. 
Target gene Primer sequence Reference 
blaTEM 
F: 5’-ATGAGTATTCAACATTTCCG -3’ 
R: 5’-CCAATGCTTAATCAGTGAGC-3’ 
20 
blaSHV 
F: 5’-CTTTACTCGCTTTATCG-3’ 
R: 5’-TCCCGCAGATAAATCACCA-3’ 
20 
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Table 2. Antibiotic resistance pattern of ESBL and non ESBL-producing isolates. 
Antibiotics 
Resistance rate 
(n=50) 
ESBL-producing 
isolates 
(n=31) 
Non ESBL-producing 
isolates 
(n=19) 
Imipenem 0 (0%) 0 (0%) 0 (0%) 
Ciprofloxacin 13 (26%) 9 (29.3%) 4 (21%) 
Levofloxacin 1 (2%) 1 (3.2%) 0 (0%) 
Gentamicin 19 (38%) 13 (41.9%) 6 (31.5%) 
Amikacin 7 (14%) 3 (9.6%) 4 (21%) 
Trimethoprim/Sulfamethoxazole 16 (32%) 11 (35.4%) 5 (26.3%) 
 
Results 
The antibiotics susceptibility results showed that 
the most effective antibiotics were imipenem 
followed by levofloxacin and amikacin. Resistance 
rates to gentamicin, ciprofloxacin and 
trimethoprim/ sulfamethoxazole were 38%, 26% 
and 32% respectively. Resistance to almost all 
tested antibiotics among ESBL-producing isolates 
were more than non ESBL-producing isolates 
without significant correlation (Table 2). 
In this study, of fifty collected E. coli isolates, 31 
isolates (62%) were ESBL-producing based on 
phenotypic method (Table 3).  
Table 3. The prevalence of ESBL-producing E. coli by 
disk diffusion method. 
ESBL–positive N (%) ESBL–negative N (%) 
31 (62) 19 (38) 
 
Also, the distribution of blaTEM and blaSHV 
genes among ESBL-producing isolates was 20 
(64.5%) and 6 (19.3%), respectively (Table 
4). 
RAPD-PCR genotyping gave us 8 (A-H) different 
types (figure 1). The most prevalent type was A, 
containing 12 isolates. All of them were ESBL-
producing stains. Of these 12 strains, 9 isolates 
carried blaTEM gene and only one of them had 
blaSHV gene.  Subsequent prevalent type was B, 
consisting of 8 isolates which 5 strains were ESBL 
producer. In B genotype blaTEM and blaSHV genes 
were found in 3 and 2 strains respectively. In our 
analysis, the H genotype was unique and 
containing only on isolate. This strain was ESBL 
producer but had not blaSHV or blaTEM gene. 
 
Table 4. The frequency of blaTEM and blaSHV genes among ESBL-producing E.coli isolates. 
blaTEM positive 
N(%) 
blaSHV positive 
N(%) 
Total 
N(%) 
blaTEM and blaSHV negative 
N(%) 
20 (64.5) 6 (19.3) 26 (83.8) 5 (16.2) 
 
 
 
Figure 1. RAPD-PCR patterns of E. coli isolates, Lanes 1 and 10; DNA size marker (100bp), Lanes A-H; eight RAPD 
genotypes. Patterns A and B were related to 12 and 8 isolates respectively. Pattern H was seen in 1 isolate exclusively. 
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Discussion 
The emergence of ESBL producer gram negative 
bacteria in the clinical setting has been reported 
from around the world.8,23,24 The present study was 
designed to evaluate the frequency of ESBL-
producing E. coli and the presence of blaTEM and 
blaSHV genes among ESBL-producing isolates. Our 
results indicated that, the prevalence of ESBL-
producing E. coli was 62%. The rate of prevalence 
in our study was higher than other studies in 
different regions of Iran. In two reports from north 
of Iran, ESBL-producing rate among E. coli 
isolates were about 26% and 30%.25,26 In a research 
in northeast of Iran, prevalence ESBL-producing of 
E. coli and K. pneumoniae  were 43.9% and 56.1% 
respectively.27 These variations may be related to 
geographical difference. 
Phenotypic method showed that, 62% of E. coli 
isolates were ESBL producer, but blaTEM and 
blaSHV genes were found among 83.8% of them. 
ESBL-producing among isolates which were 
negative for blaTEM and blaSHV genes (for example, 
type H), may be related to other ESBL responsible 
genes. The genes such as, blaCTX, blaVEB, and 
blaPER-1 have been reported among clinical isolates 
in various studies in Iran.26,28,29  Our findings 
indicated that frequency of blaTEM gene was high 
among isolates (64.5%) which is accordance with 
the several studies.29,30 
ESBL positive strains show resistance to other 
antimicrobial classes such as aminoglycosides, 
trimethoprim/ sulfamethoxazole and tetracyclines.31 
In the present study, resistance to almost all tested 
antibiotics among ESBL-producing isolates were 
more than non ESBL-producing isolates. 
In present study RAPD-PCR used for typifying 
isolates. Strains, which had similar RAPD type, 
showed same antimicrobial resistance patterns 
approximately. Molecular investigation indicated 
that most prevalent genotype was A. Most of 
genotype A isolates harbored blaTEM gene. It seems 
that blaTEM mediated resistance is most common in 
drug resistant infections. 
Most of the blaTEM positive isolates were clustered 
in an identical genotype (type A). These findings 
were in contrast to a previous study that the blaTEM 
positive strains were heterogeneous completely 
according to RAPD-PCR genotyping.32 This 
difference may be related to type of samples. In 
Pokhrel RH, et al.'s study the isolates were 
collected from various specimen, whereas the 
isolated of present study were obtained from 
diarrheal patients only. Similarly, in a 
RAPD analysis study among ESBL-producing E. 
coli isolates at a tertiary care centre in Lebanon, 
genomic variability was demonstrated.33 
Regardless of geographic region, it seems that 
closely related isolates, which had blaTEM gene had 
been colonized in evaluated gastroenteritis patients 
in Ilam. 
In order to control the wide spread of ESBL-
producing bacteria, β-lactam prescription should be 
managed carefully. Furthermore, according to 
recent studies, utilizing the new drugs or 
approaches can be effective against infectious 
diseases.34-36 
 
Conclusion 
We found most susceptibility and resistance to 
imipenem and gentamicin among E. coli isolates 
respectively. The phenotypic method demonstrated 
31 ESBL producer isolates whereas only 26 
isolates carried blaTEM and blaSHV genes. 
Antimicrobial resistance among ESBL-producing 
isolates was more than non ESBL-producing 
isolates. 
In molecular analysis, eight different RAPD types 
were determined. The most prevalent type was A. 
All of type A isolates were ESBL-producer and 
most of them had blaTEM resistance gene. 
Therefore, it seems that a blaTEM positive ESBL-
producing E. coli was common among investigated 
patients. 
 
Acknowledgements 
We would like to thank the Clinical Microbiology 
Research Center of Ilam University of Medical 
Sciences members for their friendly cooperation.  
 
Conflict of interests  
The authors claim that there is no conflict of 
interest. 
 
References  
1. Carlier M, Stove V, Wallis SC, De Waele JJ, 
Verstraete AG, Lipman J, et al. Assays for 
therapeutic drug monitoring of beta-lactam 
antibiotics: A structured review. Int J 
Antimicrob Agents. 2015;46(4):367-
75. doi:10.1016/j.ijantimicag.2015.06.016 
2. Anago E, Ayi-Fanou L, Akpovi CD, Hounkpe 
WB, Agassounon-Djikpo Tchibozo M, Bankole 
HS, et al. Antibiotic resistance and genotype of 
beta-lactamase producing Escherichia coli in 
nosocomial infections in Cotonou, Benin. Ann 
Clin Microbiol Antimicrob. 2015;14(1):5. 
doi:10.1186/s12941-014-0061-1 
3. Iredell J, Brown J, Tagg K. Antibiotic resistance 
in Enterobacteriaceae: mechanisms and clinical 
implications. BMJ.  2016;352:h6420. 
doi:10.1136/bmj.h6420 
4. Heidari H, Emaneini M, Dabiri H, Jabalameli F. 
Virulence factors, antimicrobial resistance 
pattern and molecular analysis of Enterococcal 
strains isolated from burn patients. Microb 
Pathog. 2016;90:93-7. 
doi:10.1016/j.micpath.2015.11.017 
5. Khashei R, Sedigh HSE, Alfatemi MH, 
 Pharmaceutical Sciences, December 2016, 22, 279-284  | 283 
Characterization of antimicrobial resistance pattern among ESBL-producing-Escherichia coli 
Zomorodian K. Antimicrobial resistance 
patterns of colonizing microflora on the 
personnel hands and noses working in the 
Neonatal Intensive Care Unit (NICU). World 
Appl Sci J. 2014;30:1232-7. 
doi:10.5829/idosi.wasj.2014.30.10.183 
6. Franiczek R, Krzyzanowska B. ESBL-
producing Escherichia coli isolated from 
bloodstream infections--antimicrobial 
susceptibility, conjugative transfer of resistance 
genes and phylogenetic origin. Adv Clin Exp 
Med. 2014;23(6):865-70. 
doi:10.17219/acem/37328 
7. Fircanis S, McKay M. Recognition and 
management of extended spectrum beta 
lactamase producing organisms (ESBL). Med 
Health R I. 2010;93(5):161-2.  
8. Lina TT, Khajanchi BK, Azmi IJ, Islam MA, 
Mahmood B, Akter M, et al. Phenotypic and 
molecular characterization of extended-
spectrum beta-lactamase-producing Escherichia 
coli in Bangladesh. PLoS One. 
2014;9(10):e108735. 
 doi:10.1371/journal.pone.0108735 
9. Harris PN, Tambyah PA, Paterson DL. Beta-
lactam and beta-lactamase inhibitor 
combinations in the treatment of extended-
spectrum beta-lactamase producing 
Enterobacteriaceae: time for a reappraisal in the 
era of few antibiotic options? Lancet Infect Dis. 
2015;15(4):475-85. doi:10.1016/S1473-
3099(14)70950-8 
10. Dashti AA, West P, Paton R, Amyes SG. 
Characterization of extended-spectrum beta-
lactamase (ESBL)-producing Kuwait and UK 
strains identified by the Vitek system, and 
subsequent comparison of the Vitek system 
with other commercial ESBL-testing systems 
using these strains. J Med Microbiol. 
2006;55(4):417-21. doi:10.1099/jmm.0.46177-0 
11. Woerther PL, Burdet C, Chachaty E, 
Andremont A. Trends in human fecal carriage 
of extended-spectrum beta-lactamases in the 
community: toward the globalization of CTX-
M. Clin Microbiol Rev. 2013;26(4):744-58. 
doi:10.1128/CMR.00023-13 
12. D'Andrea MM, Arena F, Pallecchi L, Rossolini 
GM. CTX-M-type beta-lactamases: a successful 
story of antibiotic resistance. Int J Med 
Microbiol. 2013;303(6-7):305-17. 
doi:10.1016/j.ijmm.2013.02.008 
13. Tasli H, Bahar IH. Molecular characterization 
of TEM- and SHV-derived extended-spectrum 
beta-lactamases in hospital-based 
Enterobacteriaceae in Turkey. Jpn J Infect 
Dis. 2005;58(3):162-7.  
14. Paterson DL, Bonomo RA. Extended-spectrum 
beta-lactamases: a clinical update. Clin 
Microbiol Rev. 2005;18(4):657-86. 
doi:10.1128/CMR.18.4.657-686.2005 
15. Trecarichi EM, Cauda R, Tumbarello M. 
Detecting risk and predicting patient mortality 
in patients with extended-spectrum beta-
lactamase-producing Enterobacteriaceae 
bloodstream infections. Future Microbiol.  
2012;7(10):1173-89. doi:10.2217/fmb.12.100 
16. Kanwar N, Scott HM, Norby B, Loneragan GH, 
Vinasco J, McGowan M, et al. Effects of 
ceftiofur and chlortetracycline treatment 
strategies on antimicrobial susceptibility and on 
tet(A), tet(B), and bla CMY-2 resistance genes 
among E. coli isolated from the feces of feedlot 
cattle. PloS One. 2013;8(11):e80575. 
doi:10.1371/journal.pone.0080575 
17. Nakhjavani FA, Emaneini M, Hosseini H, 
Iman-Eini H, Aligholi M, Jabalameli F, et al. 
Molecular analysis of typical and atypical 
enteropathogenic Escherichia coli (EPEC) 
isolated from children with diarrhoea. J Med 
Microbiol. 2013;62(2):191-5. 
 doi:10.1099/jmm.0.046516-0 
18. Clinical and Laboratory Standards Institute, 
Performance Standards for Antimicrobial 
Susceptibility Testing; Twenty-fifth 
Informational Supplement,. 2015 (m100-s25). 
19. Mansury D, Motamedifar M, Sarvari J, Shirazi 
B, Khaledi A. Antibiotic susceptibility pattern 
and identification of extended spectrum beta-
lactamases (ESBLs) in clinical isolates of 
Klebsiella pneumoniae from Shiraz, Iran. Iran J 
Microbiol. 2016;8(1):55-61.  
20. Sedighi I, Arabestani MR, Rahimbakhsh A, 
Karimitabar Z, Alikhani MY. Dissemination of 
Extended-Spectrum beta-Lactamases and 
Quinolone Resistance Genes Among Clinical 
Isolates of Uropathogenic Escherichia coli in 
Children. Jundishapur J Microbiol. 
2015;8(7):e19184. doi:10.5812/jjm.19184v2 
21. Salehi TZ, Madani SA, Karimi V, Khazaeli FA. 
Molecular genetic differentiation of avian 
Escherichia coli by RAPD-PCR. Braz J 
Microbiol. 2008;39(3):494-7. 
doi:10.1590/S1517-838220080003000015 
22. Seifi K, Kazemian H, Heidari H, 
Rezagholizadeh F, Saee Y, Shirvani F, et al. 
Evaluation of Biofilm Formation Among 
Klebsiella pneumoniae Isolates and Molecular 
Characterization by ERIC-PCR. Jundishapur J 
Microbiol. 2016;9(1):e30682. 
doi:10.5812/jjm.30682 
23. Bradford PA. Extended-spectrum beta-
lactamases in the 21st century: characterization, 
epidemiology, and detection of this important 
resistance threat. Clin Microbiol Rev. 
2001;14(4):933-51. 
doi:10.1128/CMR.14.4.933-951.2001 
 284 | Pharmaceutical Sciences, December 2016, 22, 279-284 
Kazemian et al.  
 
  
 
 
24. Bush K. New beta-lactamases in gram-negative 
bacteria: diversity and impact on the selection 
of antimicrobial therapy. Clin Infect Dis. 
2001;32(7):1085-9. doi:10.1086/319610 
25. Alizade H, Fallah F, Ghanbarpour R, 
Aflatoonian MR, Taherpour A, Sharifi H, et al. 
Genotyping of ESBL producing uropathogenic 
and diarrheagenic Escherichia coli in southeast 
of Iran. Infect Disord Drug Targets. 
2015;15(2):118-24. 
doi:10.2174/1871526515666150724113847 
26. Rezai MS, Salehifar E, Rafiei A, Langaee T, 
Rafati M, Shafahi K, et al. Characterization of 
Multidrug Resistant Extended-Spectrum Beta-
Lactamase-Producing Escherichia coli among 
Uropathogens of Pediatrics in North of Iran. 
Biomed Res Int. 2015;2015:1-7. 
doi:10.1155/2015/309478 
27. Zaniani FR, Meshkat Z, Naderi Nasab M, 
Khaje-Karamadini M, Ghazvini K, Rezaee A, et 
al. The Prevalence of TEM and SHV Genes 
among Extended-Spectrum Beta-Lactamases 
Producing Escherichia Coli and Klebsiella 
Pneumoniae. Iran J Basic Med Sci. 
2012;15(1):654-60.  
28. Jabalameli F, Mirsalehian A, Sotoudeh N, 
Jabalameli L, Aligholi M, Khoramian B, et al. 
Multiple-locus variable number of tandem 
repeats (VNTR) fingerprinting (MLVF) and 
antibacterial resistance profiles of extended 
spectrum beta lactamase (ESBL) producing 
Pseudomonas aeruginosa among burnt patients 
in Tehran. Burns. 2011;37(7):1202-7. 
doi:10.1016/j.burns.2011.05.012  
29. Feizabadi MM, Delfani S, Raji N, Majnooni 
A, Aligholi M, Shahcheraghi F, et al. 
Distribution of bla(TEM), bla(SHV), bla(CTX-
M) genes among clinical isolates of Klebsiella 
pneumoniae at Labbafinejad Hospital, 
Tehran, Iran. Microb Drug 
Resist. 2010;16(1):49-53. 
doi:10.1089/mdr.2009.0096 
30. Shahcheraghi F, Nikbin VS, Feizabadi MM. 
Prevalence of ESBLs genes among multidrug-
resistant isolates of Pseudomonas aeruginosa 
isolated from patients in Tehran. Microb Drug 
Resist. 2009;15(1):37-9. 
doi:10.1089/mdr.2009.0880 
31. Branger C, Zamfir O, Geoffroy S, Laurans G, 
Arlet G, Thien HV, et al. Genetic background of 
Escherichia coli and extended-spectrum beta-
lactamase type. Emerg Infect Dis. 
2005;11(1):54-61. doi:10.3201/eid1101.040257 
32. Pokhrel RH, Thapa B, Kafle R, Shah PK, 
Tribuddharat C. Co-existence of beta-
lactamases in clinical isolates of Escherichia 
coli from Kathmandu, Nepal. BMC Res Notes. 
2014;7(1):694. doi:10.1186/1756-0500-7-694 
33. Baroud M, Dandache I, Araj GF, Wakim 
R, Kanj S, Kanafani Z, et al. Underlying 
mechanisms of carbapenem resistance in 
extended-spectrum β-lactamase-producing 
Klebsiella pneumoniae and Escherichia 
coli isolates at a tertiary care centre in Lebanon: 
role of OXA-48 and NDM-1 carbapenemases. 
Int J Antimicrob Agents. 2013;41(1):75-9. 
doi:10.1016/j.ijantimicag.2012.08.010 
34. Andersson JA, Fitts EC, Kirtley ML, 
Ponnusamy D, Peniche AG, Dann SM, et al. 
New role for FDA-approved drugs in combating 
antibiotic-resistant bacteria. Antimicrob Agents 
Chemother. 2016;60(6):3717-29. 
doi:10.1128/AAC.00326-16 
35. Kazemian H, Ghafourian S, Heidari H, Amiri P, 
Yamchi JK, Shavalipour A, et al. Antibacterial, 
anti-swarming and anti-biofilm formation 
activities of Chamaemelum nobile against 
Pseudomonas aeruginosa. Rev Soc Bras Med 
Trop. 2015;48(4):432-6. doi:10.1590/0037-
8682-0065-2015 
36. Amini V, Kazemian H, Yamchi JK, Feyisa SG, 
Aslani S, Shavalipour A, et al. Evaluation of the 
Immunogenicity of Diphtheria Toxoid 
Conjugated to Salmonella Typhimurium-
Derived OPS in a Mouse Model: A Potential 
Vaccine Candidate Against Salmonellosis. Iran 
Red Crescent Med J. 2016;18(7):e34135. 
doi:10.5812/ircmj.34135 
 
